HALOZYME (HALO) Plans $1.05 Billion Convertible Note Offering Due 2033
Halozyme will sell $1.05 billion of convertible senior notes to institutional buyers, using part of the proceeds to buy back its 2027 and 2028 converts.
Halozyme Therapeutics (HALO) said on September 16 that it intends to offer $1.05 billion in aggregate principal amount of convertible senior notes due 2033, subject to market conditions. The San Diego drug delivery company also expects to grant initial purchasers a 13-day option for up to $150 million of additional notes, which would lift the total to $1.2 billion.
